USPTO Examiner DHAR MATASHA - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17139471PROGRAMMABLE AND PORTABLE CRISPR-CAS TRANSCRIPTIONAL ACTIVATION IN BACTERIADecember 2020July 2023Allow3011NoNo
17136080COMPOSITION AND METHOD FOR PREVENTING OR TREATING EYE DISORDERDecember 2020April 2024Allow3940NoNo
17122087ENGINEERED BI-STABLE TOGGLE SWITCH AND USES THEREOFDecember 2020June 2023Abandon3010NoNo
16973421NEXT GENERATION DESIGNER LIVER ORGANOIDS AND THEIR METHODS OF PREPARATION AND USEDecember 2020December 2024Allow4821YesNo
16972212METHODS FOR GENERATING HEMATOPOIETIC STEM CELLSDecember 2020December 2024Allow4821YesNo
17104231Gene Therapies, Systems, and Methods for MonitoringNovember 2020March 2023Abandon2810NoNo
17104607METHODS AND COMPOSITIONS FOR INDUCING TUMOR CELL DEATHNovember 2020April 2023Abandon2910NoNo
16952267ARTIFICIAL SKELETAL MUSCLE TISSUENovember 2020January 2024Abandon3821NoNo
16951220METHODS FOR ENGINEERING HUMAN PLURIPOTENT STEM CELLS FOR DIABETES THERAPY BY CO-TRANSDUCTIONNovember 2020April 2023Abandon2810NoNo
17093126METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONSNovember 2020May 2024Allow4211YesNo
17091823HYPOXIA-INDUCIBLE FACTOR-2A AS A TARGET IN PREVENTION/TREATMENT OF PARKINSON'S DISEASENovember 2020February 2023Abandon2810NoNo
17050722CRYOPRESERVATION SOLUTION AND CRYOPRESERVATION METHODOctober 2020September 2024Abandon4601NoNo
17071095VARIANTS OF CAS12A NUCLEASES AND METHODS OF MAKING AND USE THEREOFOctober 2020October 2023Allow3630YesNo
17046468SENSOR FUNCTIONALISED BIOINKOctober 2020July 2024Abandon4601NoNo
17045308DRUG SCREENING PLATFORM USING BIOMATERIAL SCAFFOLDSOctober 2020March 2024Abandon4211NoNo
17043229DIFFERENTIATION MEDIUM AND METHOD FOR PREPARING OLIGODENDROCYTE PRECURSORSeptember 2020July 2024Abandon4621NoNo
17041677METHODS OF MODULATING ANTISENSE ACTIVITYSeptember 2020January 2025Abandon5220NoNo
17028139MULTIPLEXABLE CRISPR EDITORS UTILIZING INTRACELLULAR EVOLVED APTAMERS FOR ENDOGENOUS EFFECTOR RECRUITMENTSeptember 2020March 2025Abandon5441YesYes
17011292Humanized Knock-In Mouse Expressing Human Protein C.September 2020October 2023Allow3721NoNo
17001590HUMANIZED VIPR2 COPY NUMBER VARIANT TRANSGENIC MOUSE MODEL FOR ANTIPSYCHOTIC DRUG AND GENE THERAPY DISCOVERY FOR SCHIZOPHRENIAAugust 2020April 2024Abandon4330NoNo
16965835ACTIVATION-INDUCED TISSUE-EFFECTOR CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLUAR VESICLES DERIVED THEREFROMJuly 2020June 2025Abandon5921NoNo
16833099METHOD OF TREATING OR PREVENTING HERNIA FORMATIONMarch 2020January 2024Allow4650YesNo
16629485BIOSENSORS FOR MEASURING CELL SIGNALING IN STRESSED AND HEALTHY CELLSJanuary 2020February 2024Abandon4911NoNo
16626227TRANSGENIC ANIMALS AND TRANSGENIC EMBRYOS PRODUCING AN ENGINEERED NUCLEASEDecember 2019April 2024Allow5230YesNo
16622739Genome Editing System For Repeat Expansion MutationDecember 2019May 2024Abandon5340YesNo
16622509UNIVERSAL SELF-REGULATING MAMMALIAN CELL LINE PLATFORM FOR THE PRODUCTION OF BIOLOGICSDecember 2019March 2024Allow5121YesNo
16491208COMPOSITION CONTAINING C2CL ENDONUCLEASE FOR DIELECTRIC CALIBRATION AND METHOD FOR DIELECTRIC CALIBRATION USING SAMEDecember 2019April 2023Abandon4320NoNo
16615854VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCENovember 2019December 2023Abandon4921NoNo
16616216CELL CRYOPRESERVATION FORMULATION AND CELL RECOVERY METHODNovember 2019February 2025Abandon6070NoNo
16687426HIGH ACTIVITY REGULATORY ELEMENTSNovember 2019June 2024Allow5531YesNo
16604785New Uses Of Mammalian Muscle-Derived Stem CellsOctober 2019February 2024Abandon5340YesNo
16484506FLUIDIC CHIP FOR CELL CULTURE USE, CULTURE VESSEL, AND CULTURE METHODAugust 2019October 2023Allow5021YesNo
16527152EARLY-ONSET PARKINSON'S DISEASE MODEL: (D331Y) PLA2G6 KNOCKIN MODEL, PLATFORM AND METHOD FOR DRUG SCREENING, AND KIT OF DETECTIONJuly 2019June 2024Abandon5831NoNo
16503481Preparation and application of immortalized alpha-1,3-galactosyltransferase gene knockout pig hepatocyte cell lineJuly 2019May 2023Abandon4711NoNo
15960048PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASESApril 2018May 2024Abandon6061NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DHAR, MATASHA.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DHAR, MATASHA - Prosecution Strategy Guide

Executive Summary

Examiner DHAR, MATASHA works in Art Unit 1632 and has examined 35 patent applications in our dataset. With an allowance rate of 34.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner DHAR, MATASHA's allowance rate of 34.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DHAR, MATASHA receive 2.31 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DHAR, MATASHA is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +62.0% benefit to allowance rate for applications examined by DHAR, MATASHA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.